195 related articles for article (PubMed ID: 36062548)
1. Current and promising treatment strategies in glioma.
Śledzińska P; Bebyn M; Furtak J; Koper A; Koper K
Rev Neurosci; 2023 Jul; 34(5):483-516. PubMed ID: 36062548
[TBL] [Abstract][Full Text] [Related]
2. Management of glioblastoma: State of the art and future directions.
Tan AC; Ashley DM; López GY; Malinzak M; Friedman HS; Khasraw M
CA Cancer J Clin; 2020 Jul; 70(4):299-312. PubMed ID: 32478924
[TBL] [Abstract][Full Text] [Related]
3. Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas.
Sim HW; Lorrey S; Khasraw M
Curr Neurol Neurosci Rep; 2023 Jun; 23(6):263-276. PubMed ID: 37154886
[TBL] [Abstract][Full Text] [Related]
4. [Advance of molecular subtyping and precise treatment for gliomas].
Hua W; Mao Y
Zhonghua Wai Ke Za Zhi; 2017 Jan; 55(1):63-66. PubMed ID: 28056258
[TBL] [Abstract][Full Text] [Related]
5. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
[TBL] [Abstract][Full Text] [Related]
6. A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.
Roth P; Hottinger AF; Hundsberger T; Läubli H; Schucht P; Reinert M; Mamot C; Roelcke U; Pesce G; Hofer S; Weller M
Swiss Med Wkly; 2020 Jun; 150():w20256. PubMed ID: 32557428
[TBL] [Abstract][Full Text] [Related]
7. From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.
Sun X; Turcan S
Cells; 2021 May; 10(5):. PubMed ID: 34067729
[TBL] [Abstract][Full Text] [Related]
8. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.
Weller M; Stupp R; Hegi ME; van den Bent M; Tonn JC; Sanson M; Wick W; Reifenberger G
Neuro Oncol; 2012 Sep; 14 Suppl 4(Suppl 4):iv100-8. PubMed ID: 23095825
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and Predictive Biomarkers in Gliomas.
Śledzińska P; Bebyn MG; Furtak J; Kowalewski J; Lewandowska MA
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638714
[TBL] [Abstract][Full Text] [Related]
10. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Steidl E; Filipski K; Zeiner PS; Wagner M; Fokas E; Forster MT; Ronellenfitsch MW; Divé I; Steinbach JP; Harter PN; Bähr O
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2373-2383. PubMed ID: 33538917
[TBL] [Abstract][Full Text] [Related]
11. Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma.
Yan D; Li W; Liu Q; Yang K
Front Immunol; 2022; 13():914618. PubMed ID: 35769466
[TBL] [Abstract][Full Text] [Related]
12. Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus.
Schiff D; Van den Bent M; Vogelbaum MA; Wick W; Miller CR; Taphoorn M; Pope W; Brown PD; Platten M; Jalali R; Armstrong T; Wen PY
Neuro Oncol; 2019 Jul; 21(7):837-853. PubMed ID: 30753579
[TBL] [Abstract][Full Text] [Related]
13. [Precision Medicine for IDH-mutant Diffuse Glioma(Lower-grade Glioma)].
Mukasa A
No Shinkei Geka; 2022 Jan; 50(1):8-18. PubMed ID: 35169082
[TBL] [Abstract][Full Text] [Related]
14. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
[TBL] [Abstract][Full Text] [Related]
15. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
16. [Basic principles of diagnosis and treatment of gliomas].
Wirsching HG; Weiss T; Roth P; Weller M
Nervenarzt; 2018 Jun; 89(6):692-698. PubMed ID: 29679127
[TBL] [Abstract][Full Text] [Related]
17. Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.
Richardson LG; Miller JJ; Kitagawa Y; Wakimoto H; Choi BD; Curry WT
Neurosurg Focus; 2022 Feb; 52(2):E6. PubMed ID: 35104795
[TBL] [Abstract][Full Text] [Related]
18. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
[TBL] [Abstract][Full Text] [Related]
19. Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
Li R; Chen W; Mao P; Wang J; Jing J; Sun Q; Wang M; Yu X
Exp Biol Med (Maywood); 2021 Jan; 246(2):187-196. PubMed ID: 33028081
[TBL] [Abstract][Full Text] [Related]
20. Therapies for IDH-Mutant Gliomas.
Alshiekh Nasany R; de la Fuente MI
Curr Neurol Neurosci Rep; 2023 May; 23(5):225-233. PubMed ID: 37060388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]